Placebo News and Research

RSS

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Exercise or caffeine? Study finds neither clearly beats placebo for mental fatigue

Researchers compare the effects of caffeine and aerobic exercise on mental fatigue in adults.

10 May 2026

Slow and steady wins: Low-dose peanut immunotherapy safely desensitizes 82% of preschoolers in landmark trial

A Swedish randomized trial found that slow up-dosing peanut oral immunotherapy with a low maintenance dose helped 82% of preschool children achieve sustained peanut tolerance after three years. The approach proved safer than conventional protocols, with severe reactions uncommon and strong family adherence throughout treatment.

10 May 2026

A brain-based approach may improve smoking cessation treatment success

For many people who smoke, quitting is not just a matter of willpower. It is a tug-of-war in the brain – between the pull of reward and the ability to resist.

8 May 2026

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Menopause symptoms like hot flushes can be debilitating. Dr. Katie Barber highlights new treatments, including fezolinetant, for improved patient care.

7 May 2026

Treated baby wraps may reduce malaria risk in refugee infants

Malaria remains a threat to young children in refugee settlements, where displacement, temporary housing, and limited access to healthcare reduce the effectiveness of conventional prevention tools.

7 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

Single psilocybin dose linked to lasting brain and mood changes

Researchers at UC San Francisco and Imperial College London have shown that a single dose of psilocybin, the psychedelic compound found in magic mushrooms, causes likely anatomical brain changes that last for up to a month after the experience.

5 May 2026

Study highlights breakthrough in overcoming diminishing returns of sequential IBD therapies

For patients with Crohn's disease or ulcerative colitis who have exhausted other treatment options, a new combination therapy is showing results that offer hope for one of medicine's most treatment-resistant populations, according to findings from two studies to be presented today at Digestive Disease Week® (DDW) 2026.

5 May 2026

Global MS initiative opens applications for research data access

The International Progressive MS Alliance announces the MS Clinical and Imaging Data Resource (MS CIDR) is now accepting applications for data access.

4 May 2026

Single low-dose atropine drop shows daylong effects for myopia

Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia, or nearsightedness, which affects roughly one-third of U.S. adults.

4 May 2026

Cannabis leads microdosing trends among U.S. adults, study finds

Researchers from University of California San Diego have found that microdosing - taking very small amounts of psychoactive substances - is more common among U.S. adults than previously recognized, with cannabis leading by a wide margin.

4 May 2026

Combining cannabis edibles and alcohol significantly increases driving impairment

In a study supported by the National Institute on Drug Abuse of the National Institutes of Health, Johns Hopkins Medicine researchers added to evidence that using cannabis edibles and alcohol together worsens driving impairment compared with consuming either substance alone.

4 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

Researchers leverage tamoxifen's active metabolite to improve breast cancer prevention

Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment of breast cancer.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026